[1] F. A. Greco amd J. D. Hainsworth, “Cancer of Unknown Primary Site,” In: V. T. J. DeVita, S. Hellman, S. A. Rosenberg, Eds., Cancer: Principles and Practice of Oncology, 8th Editon, Lippincott, Philadelphia, 2008, pp. 2363-2387.
[2] F. A. Greco and M. G Erlander, “Molecular Classification of Cancers of Unknown Primary Site,” Molecular Diagnosis Therapy, Vol. 13, No. 6, 2009, pp. 367-737.
[3] X. J. Ma, R. Patel, X. Wang, et al., “Molecular Classification of Human Cancers Using a 92-Gene Real-Time Quantitative Polymerase Chain Reaction Assay,” Archives of Pathology & Laboratory Medicine, Vol. 130, No. 4, 2006, pp. 465-472.
[4] N. Rosenfeld, R. Aharonov, E. Meiril, et al., “MicroRNAs Accurately Identify Cancer Tissue Origin,” Nature Biotechnology, Vol. 26, No. 4, 2008, pp. 462-469. doi:10.1038/nbt1392
[5] F. A. Monzon, M. Lyons-Weiler, L. J. Buturovic, et al., “Multicenter Validation of a 1500-Gene Expression Profile for Identification of Tumor Tissue of Origin,” Journal of Clinical Oncology, Vol. 27, No. 15, 2009, pp. 2503-2509. doi:10.1200/JCO.2008.17.9762
[6] R. Pilllai, R. Deeler, C. T. Rigl, et al., “Validation and Reproducibility of a Microarray-Based Gene Expression Test for Tumor Indentification in Formalin-Fixed, Paraffin-Embedded Specimens,” The Journal of Molecular Diagnostics, Vol. 13, No. 1, 2011, pp. 48-56. doi:10.1016/j.jmoldx.2010.11.001
[7] G. Varadhachary, D. Talantov, M. Raber, et al., “Molecular Profiling of Carcinoma of Unknown Primary and Correlation with Clinical Evaluation,” Journal of Clinical Oncology, Vol. 26, No. 27, 2008, pp. 4442-4450. doi:10.1200/JCO.2007.14.4378
[8] J. Bridgewater, R. van Laar, A. Floore, et al., “Gene Expression Profiling May Improve Diagnosis in Patients with Carcinoma of Unknown Primary,” British Journal of Cancer, Vol. 98, No. 8, 2008, pp. 1425-1430. doi:10.1038/sj.bjc.6604315
[9] H. M. Horlings, R. van Laar, J.-M. Kerst, et al., “Gene Expression Profiling to Identify the Histogenetic Origin of Metastatic Adenocarcinomas of Unknown Primary,” Journal of Clinical Oncology, Vol. 26, No. 27, 2008, pp. 4435-4439. doi:10.1200/JCO.2007.14.6969
[10] F. A. Monzon, F. Medeiros, M. Lyons-Weiler, et al., “Identification of Tissue of Origin in Carcinoma of Unknown Primary with a Microarray-Based Gene Expression Test,” Diagnostic Pathology, Vol. 5, 2010, pp. 3-7. doi:10.1186/1746-1596-5-3
[11] F. A. Greco, D. R. Spigel, D. A. Yardley, et al., “Molecular Profiling in Unknown Primary Cancer Tissue of Origin Prediction,” The Oncologist, Vol. 15, No. 5, 2010, pp. 500-506. doi:10.1634/theoncologist.2009-0328
[12] F. A. Greco and N. Pavlidis, “Treatment for Patients with Unknown Primary Carcinoma and Unfavorable Prognostic Factors,” Seminars in Oncology, Vol. 36, No. 1, 2009, pp. 35-74. doi:10.1053/j.seminoncol.2008.10.005
[13] L. B. Saltz, S. Clarke, E. Diaz-Rubio, W. Scheithauer, et al., “Bevacizumab in Combination with Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal cancer: A Randomized Phase III Study,” Journal of Clinical Oncology, Vol. 26, No. 12, 2008, pp. 2013-2019. doi:10.1200/JCO.2007.14.9930
[14] F. F. Kabbinavar, H. I. Hurwitz, J. Yi, et al., “Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients from Two Randomized Clinical Trials,” Journal of Clinical Oncology, Vol. 27, No. 2, 2000, pp. 199-205. doi:10.1200/JCO.2008.17.7931
[15] D. Talantov, J. Baden and T. Jaktoe, “A Quantitative Reverse Transcriptase-Polymerase Chain Reaction Array to Identify Metastatic Carcinoma Tissue of Origin,” The Journal of Molecular Diagnostics, Vol. 8, No. 3, 2006, pp. 320. doi:10.2353/jmoldx.2006.050136
[16] S. Y. Park, B. H. Kim, S. H. Kim, et al., “Panels of Immunohistochemical Markers Help Determine Primary Sites of Metastatic Adenocarcinomas,” Archives of Pathology & Laboratory Medicine, Vol. 131, No. 10, 2007, pp. 1561-1567.
[17] K. A. Oien, “Pathologic Evaluation of Unknown Primary Cancer,” Seminars in Oncology, Vol. 36, No. 1, 2009, pp. 8-37. doi:10.1053/j.seminoncol.2008.10.009
[18] P. J. Zhang, M. hah, G. W. Spiegel, et al., “Cytokeratin 7 Immunoreactivity in Rectal Adenocarcinoma,” Applied Immunohistochemistry & Molecular Morphology, Vol. 11, No. 4, 2003, pp. 306-310. doi:10.1097/00129039-200312000-00005
[19] G. R. Varadhachary, M. N. Raber, A. Matamoros, et al., “Carcinoma of Unknown Primary with a Colon-Cancer Profile-Changing Paradigm and Emerging Definitions,” The Lancet Oncology, Vol. 9, No. 6, 2008, pp. 596-600. doi:10.1016/S1470-2045(08)70151-7